Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 15/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238057 | 0.85 | GPR84 (0.67) | GPR84MPOSLC6A4HTR1A | |
| SCHEMBL2542732 | 0.81 | GPR84 (0.71) | GPR84MPOSLC6A4HTR1A | |
| SCHEMBL30579356 | 0.81 | GPR84 (0.71) | GPR84MPOSLC6A4HTR1A | |
| SCHEMBL25882724 | 0.81 | GPR84 (0.56) | GPR84MPOSLC6A4HTR1A | |
| Hydrochloric Acid SCHEMBL7819150 | 0.80 | GPR84 (0.69) | GPR84MPOSLC6A4HTR1A | |
| SCHEMBL5791055 | 0.77 | GPR84 (0.59) | GPR84MPOSLC6A4HTR1A | |
| SCHEMBL4785843 | 0.76 | GPR84 (0.63) | GPR84MPOSLC6A4HTR1A | |
| SCHEMBL30483767 | 0.76 | GPR84 (0.63) | GPR84MPOSLC6A4HTR1A | |
| SCHEMBL4506788 | 0.76 | GPR84 (0.63) | GPR84MPOSLC6A4HTR1A | |
| SCHEMBL25747528 | 0.76 | GPR84 (0.63) | GPR84MPOSLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4165023-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-115867532-A | Inhibitors of APOL1 and uses thereof | 弗特克斯药品有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | GPR84 1353/4885MPO 4464/4885SLC6A4 32/4885 |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | GPR84 3762/4885MPO 1381/4885SLC6A4 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.